2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148604
    Imuracetam 67542-41-0 98%
    Imuracetam is a racetam compound. Racetam compounds have good cognitive-enhancing effects.
    Imuracetam
  • HY-148605
    Aloracetam 119610-26-3 98%
    Aloracetam is a γ-aminobutyric acid cyclic derivative that can pass through the blood-brain barrier and has a significant enhancing cognitive function effect. Aloracetam improves the blood perfusion of brain tissue, increases the synthesis of proteins, ATP and acetylcholine in the brain, enhances the excitatory conduction effect of cholinergic nerves, and reduces the damage to brain tissue caused by cerebral vascular diseases. Aloracetam also has certain anti-epileptic, anti-inflammatory, analgesic and anti-depressant effects.
    Aloracetam
  • HY-148611
    NSC339614 potassium 1135037-53-4 98%
    NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptor enhancer with the activity of enhancing neuronal responses to specific NMDA receptors. NSC339614 potassium can selectively enhance the signaling of GluN1/GluN2C and GluN1/GluN2D receptors without affecting other NMDA receptors. The mechanism of action of NSC339614 potassium does not compete with agonists of L-glutamate or glycine, nor does it depend on membrane potential. The activity of NSC339614 potassium depends on the specific structure of the agonist ligand binding domain, showing its potential as a novel pharmacological agent for studying the function of NMDA receptor subtypes and providing new lead compounds for a variety of neurological diseases.
    NSC339614 potassium
  • HY-148717
    NSC363998 free base 159357-82-1 98%
    NSC363998 (free base) is an orally active compound. NSC363998 (free base) can suppress rCGG90 induced neurotoxicity. NSC363998 (free base) can be used for the research of neurodegenerative disorder such as Fragile X associated tremor/ataxia syndrome (FXTAS).
    NSC363998 free base
  • HY-148718
    4-Chloro Trazodone hydrochloride 1263278-77-8 98%
    4-Chloro Trazodone hydrochloride is an isomer of Trazodone hydrochloride (HY-B0478). Trazodone hydrochloride is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders.
    4-Chloro Trazodone hydrochloride
  • HY-148747
    Ganglioside GD3 (d18:1/12:0) 138749-26-5 98%
    Ganglioside GD3 (d18:1/12:0) is a type of glycosphingolipid, the d18:1 indicates the sphingosine base, and the 12:0 represents the fatty acid part which is lauric acid. Ganglioside GD3 (d18:1/12:0) is a crucial intermediate in the biosynthesis pathway of gangliosides and is mainly found in the brain tissues of mammals. Ganglioside GD3 (d18:1/12:0) plays significant roles in development, cell signal transduction, and various diseases.
    Ganglioside GD3 (d18:1/12:0)
  • HY-148750
    PTX-BD10-2 1627834-10-9 98%
    PTX-BD10-2 (BD10-2) is an orally active TrkB/C modulator. PTX-BD10-2 ameliorates BFCN degeneration. PTX-BD10-2 restores cholinergic neurite integrity, alleviates cholinergic neurite atrophy. PTX-BD10-2 can be used in the research of Alzheimer's disease.
    PTX-BD10-2
  • HY-148828
    LSP-GR3 1235945-37-5
    LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.
    LSP-GR3
  • HY-148866
    Cavα2δ1&NET-IN-3 2143584-82-9 98%
    Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has Kis of 100-500 nM for human α2δ-1 subunit of Cav2.2 calcium channel and NET, respectively.
    Cavα2δ1&NET-IN-3
  • HY-148909
    Isopropyl dodec-11-enylfluorophosphonate 623114-64-7 98%
    Isopropyl dodec-11-enylfluorophosphonate (IDEFP) is an organophosphorus ester that antagonizes the central cannabinoid receptor (CB1) and inhibits FAAH with similar potencies (IC50 = 2 nM).
    Isopropyl dodec-11-enylfluorophosphonate
  • HY-14895B
    Fabomotizole dihydrochloride 189638-30-0 98%
    Fabomotizole dihydrochloride is an anxiolytic agent. Fabomotizole dihydrochloride produces anxiolytic and neuroprotective effects without any muscle relaxant actions.
    Fabomotizole dihydrochloride
  • HY-148961
    HTL-9936 1438242-59-1 98%
    HTL-9936 is a selective M1 muscarinic acetylcholine receptor (M1-mAChR) agonist. HTL-9936 is promising for research of neurodegenerative disorders (e.g., Alzheimer’s).
    HTL-9936
  • HY-149012
    AChE/hCA I/II-IN-1 2049681-10-7 98%
    AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of AChE/Hca with IC50 values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes.
    AChE/hCA I/II-IN-1
  • HY-149014
    OX2R-IN-1 2639148-08-4 98%
    OX2R-IN-1 (compound 15) is a low cytotoxicity profile OX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value of 484 μM. OX2R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life.
    OX2R-IN-1
  • HY-149065
    D-685 2893801-00-6 98%
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.
    D-685
  • HY-149087
    MR2938 1044870-65-6 98%
    MR2938 is a potent AChE inhibitor, with an IC50 of 5.04 μM. MR2938 also suppresses NO production obviously (IC50 = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research.
    MR2938
  • HY-149090
    AChE/BuChE/MAO-B-IN-2 3044829-88-8 98%
    AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent AChE/BuChE inhibitor and showed good blood brain barrier (BBB) permeability in vitro with an IC50 value of 5.3 μM, 12.4 μM, 1.9±0.08 μM, for AChE, BuChE, huMAO-B, respectively. AChE/BuChE/MAO-B-IN-2 (compound 4b) can inhibit excess AChE/BuChE in Alzheimer's disease (AD) brain. AChE/BuChE/MAO-B-IN-2 (compound 4b) can be used in anti-Alzheimer's research.
    AChE/BuChE/MAO-B-IN-2
  • HY-149097
    ITH12711 3042876-07-0 98%
    ITH12711 is a PP2A ligand. ITH12711 is able to cross the blood-brain barrier (BBB). ITH12711 exerts neuroprotection via restoration of PP2A-phosphatase activity.
    ITH12711
  • HY-149211
    AChE/BChE-IN-12 98%
    AChE/BChE-IN-12 (compound 10b), a 3,5-dimethoxy analogue, is a potent AChE, BChE, and β-secretase-1 (BACE-1) inhibitor, with IC50 values of 2.57, 3.26, and 10.65 μM, respectively. AChE/BChE-IN-12 crosses the blood-brain barrier via passive diffusion and inhibits the self-aggregation of amyloid-β monomers. AChE/BChE-IN-12 can be used for Alzheimer’s disease (AD) research.
    AChE/BChE-IN-12
  • HY-149219
    BIBD-124 2716871-93-9 98%
    BIBD-124 binds amyloid beta (Aβ) plaque with an IC50 value of 9.51 nM. [18F]BIBD-124 can be used as radiotracer of Aβ plaques.
    BIBD-124
Cat. No. Product Name / Synonyms Application Reactivity